Image-guided radiotherapy developer ViewRay saw revenue grow for its second-quarter financial results (end-June 30), compared with the same period a year ago.
Total revenue for the quarter was $300,000, up 50% from $200,000 in the same period last year. Total revenue for the six-month period was $5.8 million, compared with $500,000 for the same six months last year, due in part to three new orders the firm received for its MRIdian system in the second quarter.
The company's net loss for the second quarter was $12.1 million, compared with a net loss of $12.2 million in the same period last year. The firm's net loss for the six-month period was $25.5 million, compared with $20.6 million in 2015.
ViewRay noted that its MRIdian system is not yet available for sale in the U.S., but the firm expects to submit for U.S. Food and Drug Administration 510(k) clearance and the European CE Mark by the end of the year. In addition, ViewRay has a backlog of $100.7 million, representing 18 signed sales contracts, as of June 30.
